ANDREW J. SCHWAB   Managing Partner, 5AM Ventures

Prior to founding 5AM in 2002, Andrew was a Principal at Bay City Capital. After joining Bay City Capital in 1999, he led the firm’s investment and merchant banking activities for such companies as Cubist, Metabolex, PTC Therapeutics, Symyx and Syrrx. Previously Andrew was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities. At 5AM, he has led the firm’s investments in and served on the Boards of Directors of Biodesy, Cleave, DVS (acquired by Fluidigm), Flexion (IPO), Ikaria, Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed), Panomics (acquired by Affymetrix), RuiYi, Synosia (acquired by Biotie) and Viveve. Mr. Schwab received a B.S. with Honors in Genetics & Ethics from Davidson College and was a member of Davidson’s 1992 Final Four soccer team.

BILL BURKOTH   Executive Director, Pfizer Ventures

Since joining Pfizer Ventures, the venture capital arm of Pfizer Inc., in early 2004, Bill has played an instrumental role in numerous new venture capital investments, including Avid Radiopharmaceuticals (acquired by Eli Lilly), Clovis Oncology (Nasdaq: CLVS), DVS Sciences (acquired by Fluidigm), Evolution Benefits (acquired by Genstar Capital), and HandyLab (acquired by Becton Dickinson). Bill currently also serves on the board of directors of NeuMoDx Molecular, Novocure, and RefleXion Medical and as a board observer of Epic Sciences, HD Biosciences (Shanghai, China), M2S, and Nodality. Prior to joining Pfizer, Bill worked in Business Development at Galileo Pharmaceuticals and at IntraBiotics Pharmaceuticals. Prior to his roles in business development, Bill was an analyst at Bay City Capital. Bill received a BA in chemistry from Whitman College and an MBA from Columbia Business School.


Joe Victor brings more than 30 years of experience fostering product innovation and building value for customers, shareholders, and employees. Most recently, he was CEO of privately held DVS Sciences, a designer and manufacturer of a transformational bioanalytical platform including high-end mass cytometry instruments and associated consumables. DVS was sold in early 2014 to Fluidigm, Inc., a leading Life Sciences publicly held company.  Prior to DVS, Mr. Victor was CEO of Applied Precision Inc., a manufacturer of high performance microscopy systems for life sciences research and drug development acquired by GE Healthcare in 2011. Before that he drove significant sales growth, new product development and overall profitability of the Applied Precision business in the roles of President, Sr. VP Life Sciences, VP R&D / Operations, and VP R&D. Prior to Applied Precision, Mr. Victor held various executive management and technical positions in the high technology, aviation, and energy markets.  Mr. Victor holds an MBA from UCLA and MS and BS degrees in engineering from the University of Washington. Mr. Victor is based in the Seattle area and currently serves on the following company board of directors:  Biodesy, Glencoe Software, Precision Nanosystems, Purigen, and RareCyte.  Mr Victor also serves as an advisory board member to the Harvard Program in Therapeutic Science and the UC Davis Ecosystem for Biophotonics Innovation.


Josh is the Founder of Biodesy and the inventor of the Second Harmonic Generation (SHG) technique for studying biological molecules. Josh was awarded a number of NSF and NIH grants and obtained key scientific breakthroughs that galvanized the scientific and venture capital communities.  Previously, Josh was a postdoctoral fellow in the Dept. of Chemistry at Columbia University and the Dept. of Physics at Utrecht University in the Netherlands, as well as a guest researcher at the Cavendish Laboratory at the University of Cambridge, UK. His expertise and interests are in the areas of Biophysics and Physical Chemistry. At Biodesy he leads a team focused on creating novel techniques with SHG and applying them to problems in drug discovery and structural biology.  Josh received his PhD from Stanford University where he studied the reaction center protein, the marvelous engine at the heart of photosynthesis which converts light into chemical energy.


Hans-Joachim Boehm  

Dr. Hans-Joachim Boehm, Ph.D. was Global Head of Small Molecule Research at Roche until 2015. Prior to this, Dr. Boehm served in various positions across the organization including the President and Research Site Head of Roche Palo Alto as well as the Head of Non-Clinical Development at Roche Basel.  Before joining Roche in 1996, Dr. Boehm held positions with BASF in Ludwigshafen as a Computational Chemist as well as with Siemens in Munich, in the field of Microelectronics. He obtained his Ph.D. in Theoretical Chemistry from the University of Karlsruhe and currently serves as an Adjunct Professor of Bioinformatics at the University of Basel. He is also a member of the Swiss Science and Innovation Council which is the advisory board for the Swiss Federal Council for issues related to science, education, research and innovation.

Andrej Sali  

Andrej Sali received his BSc degree in chemistry from the University of Ljubljana, Slovenia, in 1987; and his PhD from Birkbeck College, University of London, UK, in 1991, under the supervision of Professor Tom L. Blundell, where he developed the MODELLER program for comparative modeling of protein structures. He was then a postdoc with Professor Martin Karplus at Harvard University as a Jane Coffin Childs Memorial Fund fellow, studying lattice Monte Carlo models of protein folding. From 1995 to 2002, he was first an Assistant Professor and then an Associate Professor at The Rockefeller University. In 2003, he moved to University of California, San Francisco, as a Professor of Computational Biology in the Department of Bioengineering and Therapeutic Sciences, Department of Pharmaceutical Chemistry, and California Institute for Quantitative Biosciences (QB3). He was a Sinsheimer Scholar (1996), an Alfred P. Sloan Research Fellow (1998), an Irma T. Hirschl Trust Career Scientist (2000), the recipient of the Zois Award of Science Ambassador of Republic of Slovenia (2007), and elected a Fellow of International Society for Computational Biology (2014). He has been an Editor of Structure since 2002. He is also a Founder of Prospect Genomix that merged with Structural Genomix (2001); and of Global Blood Therapeutics (2012). Dr. Sali develops and applies computational methods for determining and modulating structures and functions of proteins and their assemblies.

Richard Ulevitch  

Richard J. Ulevitch, Ph.D. joined 5AM Ventures in February 2008 as a Venture Partner. Previously he was Chairman of 5AM’s Scientific Advisory Board while serving as Professor and Chairman of the Department of Immunology at The Scripps Research Institute in La Jolla, California. He remains as Professor and Chairman Emeritus at The Scripps Research Institute. For nearly three decades, Dr. Ulevitch has performed research to understand the role of the immune system in human disease. He serves as a scientific advisor to Aravis Ventures, a European life science venture capital fund and previously served as an advisor to the Lombard Odier Immunology Fund, where he evaluated numerous biotechnology companies over a fifteen-year span. Dr. Ulevitch serves or has served on the Scientific Advisory Boards of Arvinas, Biodesy, Bird Rock Bio, Cidara (NASDAQ: CDTX), Cleave, Envoy (acquired by Takeda), Ideaya, Igenica, Ikaria (acquired by Mallinckrodt), Pulmatrix (NASDAQ: PULM) as well as on the Board of PhaseRx. Dr. Ulevitch received an A.B. from Washington and Jefferson College and a Ph.D. in Biochemistry from the University of Pennsylvania. Dr. Ulevitch is based in the Menlo Park, CA office.